Genetic Testing for Hereditary Ataxias - Medicare Advantage

This Humana Medicare Advantage coverage article considers genetic testing for hereditary ataxias (CANVAS/RFC1, Friedreich ataxia/FXN, and spinocerebellar ataxias) medically reasonable and necessary only when MolDX technical assessment OR FDA approval/clearance (within labeling) is present and specific clinical utility criteria are met (age and required signs/symptoms, and supportive documentation). Tests lacking required clinical indications, those performed for screening or risk assessment without symptoms, investigational tests not in trials, or tests without MolDX/FDA approval where required are excluded.

"Genetic testing of RFC1 gene (0378U) will be considered medically reasonable and necessary to aid in the diagnosis of CANVAS when MolDX Program approved technical assessment OR FDA approval/clearan..."

Sign up to see full coverage criteria, indications, and limitations.